![]()
|
|
||||||||
J. Biol. Chem., Vol. 276, Issue 43, 39618-39628, October 26, 2001
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
§¶,
, and
**
From the
Laboratory of Microbiology, The Rockefeller
University, New York, New York 10021 and the § Molecular
Genetics Unit, Instituto de Tecnologia Química e
Biológica, Universidade Nova de Lisboa, 2780 Oeiras,
Portugal
Received for publication, July 9, 2001, and in revised form, August 22, 2001
| |
ABSTRACT |
|---|
|
|
|---|
The recently identified murMN operon
of Streptococcus pneumoniae encodes enzymes involved in the
synthesis of branched structured muropeptides of the pneumococcal cell
wall peptidoglycan. Its inactivation was shown to cause production of a
peptidoglycan composed exclusively of linear muropeptides and a
virtually complete loss of resistance in penicillin-resistant strains.
The studies described in this communication follow up these
observations in several directions. The substrate of the MurM-catalyzed
reaction (addition of alanine or serine) was identified as the
lipid-linked N-acetylglucosamine-muramyl pentapeptide.
Different murM alleles from several
penicillin-resistant S. pneumoniae strains, each with a
characteristic branched peptide pattern, were cloned into pLS578, a
pneumococcal plasmid capable of replicating in S. pneumoniae, and transformed into the penicillin-susceptible
laboratory strain R36A. All transformants remained
penicillin-susceptible; however, their cell wall composition changed in
directions corresponding to the muropeptide pattern of the strain from
which the murM allele was derived. This suggests that the
muropeptide composition of the pneumococcal cell walls is determined by
the particular murM allele carried by the cells. A 30-amino
acid long sequence within the MurM protein was shown to be the main
determinant of the specificity of the reaction (addition of alanine
versus serine).
The synthesis of the peptidoglycan in bacteria may be divided into
three stages: in the first, cytoplasmic, stage several consecutive
enzymatic reactions synthesize the peptidoglycan building block, the
UDP-MurNAc-pentapeptide. In the case of Streptococcus pneumoniae and several other bacteria, the pentapeptide chain is composed of L-alanine, D-isoglutamine,
L-lysine, D-alanine, D-alanine,
with the latter representing the C-terminal residue. The second stage
of synthesis occurs in the plasma membrane where the peptidoglycan
building block is linked to a bactoprenol residue and may undergo a
"maturation process" by several as yet not well understood
enzymatic reactions. These may include addition of short peptides to
the lysine epsilon amino group in some or all of the stem peptides; and
amidation of the second stem peptide residue, usually a glutamate, to
glutamine. After addition of an N-acetyl glucosamine
residue, the bactoprenol-linked and structurally completed disaccharide
pentapeptide peptidoglycan precursor is transferred to the outer side
of the plasma membrane for presentation to proteins (monofunctional
transglycosylases, penicillin binding proteins) that take part in the
assembly of the macromolecular peptidoglycan.
The pneumococcal peptidoglycan is composed of both linear and branched
muropeptides, the latter of which carry short dipeptide branches. The
chemical nature of the branched peptides, seryl "alanine or alanyl"
alanine, i.e. the type of muropeptide they are attached to
and the proportion of muropeptides carrying branches vary from strain
to strain (1-3). The identification of the murMN operon
opened up new experimental approaches for the study of the mechanism of
synthesis and physiological role of branched peptides. Most
interestingly, inactivation of the murMN was shown to cause
not only the production of cell wall peptidoglycan composed exclusively
of linear muropeptides but also a complete loss of the resistant
phenotype in penicillin-resistant strains (4). Several
penicillin-resistant isolates were shown to carry murM genes
with unique polymorphic regions, which seem to correlate with the
preponderance of seryl-alanine or alanyl-alanine branches in the
peptidoglycan (5). Selective inactivation of murM and murN showed that the protein products of these genes act in
sequence: murM being involved with the addition of the first
amino acid (serine or alanine) and murN involved with the
addition of second amino acid of the bridge (alanine) (6).
The main purpose of the studies described here was to identify the
substrate of the MurM-catalyzed reaction and to better define the roles
of various murM alleles in defining cell wall composition
and penicillin resistance.
Strains, Growth Conditions, and Antibiotic Susceptibility
Tests--
All strains and plasmids used in this study are listed
below in Table I. S. pneumoniae strains were
grown in a casein-based semisynthetic medium at 37 °C without
aeration, as previously described (1). S. pneumoniae strains
containing pLS578 or its derivatives were grown in the presence of 1 µg/ml tetracycline, and Escherichia coli strains
containing pGEM-3Z plasmid or its derivatives were grown in the
presence of 100 µg/ml ampicillin (Sigma Chemical Co.).
Penicillin-resistance levels (minimal inhibitory concentration,
MIC1) were determined by the
E test following manufacturer's guidelines (AB Bidosk, Solna, Sweden).
DNA Techniques--
All routine DNA manipulations were performed
using standard methods (11, 12). Chromosomal DNA from S. pneumoniae was isolated as described previously (13). Plasmids
were isolated using the Wizard Plus Minipreps or Midipreps DNA
purification system (Promega), and PCR products were purified using the
Wizard PCR Preps DNA purification system (Promega). Oligonucleotides
were purchased from Life Technologies, Inc. DNA sequencing was done at
the Rockefeller University Protein/DNA Technology Center with the
BigDye terminator cycle sequencing method and either the 3700 DNA
analyzer for capillary electrophoresis or the ABI Prism 377 DNA
sequencer for slab-gel electrophoresis. Nucleotide and derived amino
acid sequences were analyzed using DNASTAR software.
Construction of S. pneumoniae Lacking murM--
To isolate a
mutant of the penicillin-resistant strain Pen6 lacking murM
gene, we transformed Pen6 with a PCR fragment that included the 2-kb
fragment from pJDC9, containing the erm marker, flanked by
the regions upstream and downstream of murM.
To obtain this PCR fragment the upstream and downstream segments of
murM were amplified from chromosomal DNA of strain Pen6 by
PCR with PfuTurbo DNA polymerase (Stratagene). First, the
0.46-kb PCR fragment containing the upstream region of murM
was amplified with primers ZOO45EC
(5'-AGCGAATTCGGTTTTGACTACTACACGGC-3') and ZOO46BM
(5'-ATAGGATCCTTTCCCAGTAGTACCACTCG-3'), digested with
EcoRI and BamHI and cloned into plasmid pGEM-3Z
generating plasmid pZ009. The EcoRI and BamHI
restriction sites are underlined in the primers. Next the
HindIII/PstI-digested 0.54-kb PCR fragment
containing the downstream region of murM was amplified with
primers ZOO47PS (5'-GCGCTGCAGAGTCGGCAGCGACTCATAGAAT-3') and
ZOO2BM (5'-TATGGATCCAGTCTCGCGCTTCTGCTTTTC-3'), and was cloned into
pZ009 yielding pZ0010. The underlined sequence indicates the
PstI restriction site. Finally the 2-kb
BamHI/ClaI fragment from pJDC9 containing the
erm marker was cloned into the
BamHI/AccI-digested plasmid pZOO10 generating
pZ0011. Plasmid pZ0011 contains the erm marker flanked by
the upstream and downstream regions of murM. The
transforming DNA used to prepare the murM null mutant of
strain Pen6 was a PCR fragment of plasmid pZOO11 amplified with primers
ZOO30 (5'-ATATTCTCTACGTTCAGAGG-3') and ZOO45EC
(5'-AGCGAATTCGGTTTTGACTACTACACGGC-3'). The conditions used for the PCR
reactions were: 94 °C for 5 min; 30 cycles of 94 °C for 30 s, 53 °C for 30 s, and 72 °C for 2 min; and one final extension step of 72 °C for 5 min. This PCR program was used for all
amplifications except the extension time at 72 °C, which was different depending on the size of the PCR fragment to be amplified. The deletion of murM in the erythromycin-resistant
Pen6 Transformation of S. pneumoniae--
Transformation of S. pneumoniae R36A strain was carried out similarly to the already
described procedure (14) except that the concentration of peptide
pheromone was 500 ng/ml and the transforming reaction was held at
37 °C for 4 h before plating in selective plates of TSA+3%
(v/v) sheep blood and 1 µg/ml tetracycline. The different
murM alleles cloned in pLS578 and transformed into R36A strain were specifically amplified with primers that hybridize in the
plasmid: TETDPLS (5'-CCTATGGAAGTTGATCAGTC-3') and CATR (5'-CATGRTAACCATCACAWACAG-3').
Construction and Cloning of the Different murM Alleles into S. pneumoniae--
Several murM constructs were prepared, each
in the S. pneumoniae plasmid pLS578, a plasmid with a strong
promoter that can replicate in S. pneumoniae (10). Three
S. pneumoniae strains were used as sources of
murM alleles: the penicillin-susceptible laboratory strain
R36A, the penicillin-resistant strain DE1 producing alanine-rich
branches in the cell wall, and the penicillin-resistant strain KY17
producing serine-rich branches.
The first one of such plasmid constructs carried the murM
allele from strain R36A. The murM gene was amplified as a
PCR fragment from the chromosomal DNA using primers ZOO48HI
(5'-CCCAAGCTTAAAATACTGGAGGAAAGAGAG-3') and ZOO49NC
(5'-CATGCCATGGGCCATATAC
The second and third plasmids were constructed by the same procedure
using chromosomal DNA either from penicillin-resistant strain DE1
(plasmid pM2) or from the penicillin-resistant strain of KY17 (plasmid pM3).
MurM Chimera Mutants--
Another set of plasmids was
constructed in such a way that segments of the 406-amino acid long
MurM would be derived from various murM alleles carried by
the penicillin-susceptible strain R36A or the penicillin-resistant
strains DE1 or KY17.
The first one of these plasmids, pM9, contained a cloned chimeric MurM
that was composed of residues 1-240 with equal sequence to the MurM of
the penicillin-susceptible strain R36A fused the remaining 166 amino
acids residues of the penicillin-resistant strain DE1.
Plasmid pM9 was constructed in several steps. A PCR fragment encoding
for the C terminus 166 amino acid residues (from 241 to 406) of strain
DE1 was amplified with the primers MMUT4
(5'-CCCAAGCTTGCTCTAGATGTTTCTAAGCGTTTAAG-5', where the HindIII and XbaI restriction sites are
underlined) and ZOO49NC (see above) from chromosomal DNA and cloned
into the HindIII/NcoI-digested E. coli
plasmid pSF22 (pGEM-3Z carrying a promoterless murN and an
NcoI restriction site (see Table I below), yielding plasmid pSF24. Next, the full murM gene was reconstructed by cloning
in this plasmid (digested with HindIII and XbaI)
the PCR product obtained from the chromosomal DNA of strain R36A with
the primers ZOO48HI (see above) and MMUT3
(5'-GCATCTAGAGTTGCCAAGGTGATGTAG-3', where the
XbaI restriction site is underlined), generating a plasmid named pSF25. Finally, the chimeric murM gene was transferred
from pSF25 to the pneumococcal plasmid pLS578 by the following
operations. The chimeric mutant murM was amplified from
plasmid pSF25 using primers ZOO48HI and ZOO49NC (see above) and cloned
into the HindIII/NcoI-digested pLS578 plasmid.
This pneumococcal plasmid, carrying the murM chimera mutant
gene from the penicillin-resistant strain R36A and DE1 was named pM9.
The second chimeric plasmid pM10 included a PCR fragment that encoded
for the 240 amino acid residues from the N terminus of the
penicillin-resistant strain KY17 (from 1 to 240) fused with the
remaining 166 amino acid residues from another penicillin-resistant strain DE1 (from 241 to 406).
Plasmid pM10 was constructed in a way similar to that used in the
construction of pM9. A PCR fragment encoding for the 240 amino acid
residues from the position 1-240 was amplified with the primers
ZOO48HI and MMUT3 (see above) from the KY17 chromosomal DNA and cloned
into the HindIII/XbaI-digested pSF24 plasmid,
generating the plasmid pSF26. Procedures similar to the ones used in
the construction of pM9 were employed for the transfer of the
murM chimera from the E. coli plasmid pSF26 to
the pneumococcal plasmid pLS578 generating the plasmid pM10.
An additional set of plasmids carrying chimeric murM mutants
were constructed to more precisely define the region controlling the
specificity of the reaction catalyzed by the MurM protein.
Plasmid pM11 carried a murM allele that was identical to
that from strain KY17 (the MurM of which mainly adds serine residues to
the muropeptide cross-bridges) except for the position between residues
244 and 298, which was replaced by the corresponding sequence from the
murM of strain DE1 (the MurM of which mainly adds alanine
residues to the muropeptide cross-bridges).
Plasmid pM11 was constructed in several steps. A PCR fragment
comprising the sequence that encodes for the residues from position 300 to the end of the MurM protein (the 106 amino acid residues from the C
terminus) of strain KY17 was amplified with primers ZOO49NC (see above)
and MMUT18 (5'-CGCAAGCTTCTCGAGTTTGGTACTACCTCTGTCAATC-3' from plasmid pSF27, where the HindIII and XhoI
restriction sites are underlined). This PCR fragment was cloned into
the HindIII/NcoI-digested plasmid pSF22, yielding
plasmid pSF28. Next, the full gene was reconstructed by cloning in
pSF28 (digested with HindIII and XhoI) the PCR
product that encoded the amino acid residues from position 1 to 300, obtained with the primers ZOO48HI (see above) and MMUT19 (5'-TTCCTCGAGACTCAAAGTAGCCGCTAAG-3') from pSF26 (the
XhoI restriction site is underlined). The resulting plasmid,
pSF29, carried a chimeric MurM protein that was equal to the KY17 MurM
except between residues 244 and 298, which were the same as those found
in the DE1 MurM. Finally, the chimeric murM gene was
amplified from plasmid pSF29 using primers ZOO48HI and ZOO49NC (see
above) and cloned into the HindIII/NcoI-digested
pLS578 plasmid, yielding the plasmid pM11.
An additional murM chimera mutant, pM12, was constructed in
a similar way as described for pM11, but this time only the segment between residues 244 and 274 was derived from the MurM of strain DE1.
As in the case of pM11, here too, the chimera mutant was initially
constructed in an E. coli plasmid. The PCR product obtained from plasmid pSF27 with primers ZOO49NC and MMUT16
(5'-CGCAAGCTTCTCGAGGAATTGACTTTCCTGCAGG-3', where the
HindIII and XhoI restriction sites are
underlined), was first cloned into the
HindIII/NcoI-digested pSF22 plasmid. The
resulting plasmid, pSF30, carried a DNA fragment that encoded the
residues from 276 to the end of the protein (the last 131 residues from
the C terminus) of the murM of strain KY17. The DNA fragment
coding for the remaining 275 amino acids was amplified with primers
ZOO48HI (see above) and MMUT17
(5'-TTCCTCGAGTAAACGTTCTTTTTCTTTTATATTTTCCTG-3') from pSF26
and cloned to the HindIII/XhoI-digested pSF30
plasmid, yielding the plasmid pSF31. This plasmid carried a chimeric
MurM protein that was equal to the KY17 MurM except for the position between residues 244 and 274, which came from the murM of
strain DE1. After amplification from plasmid pSF31 with primers ZOO48HI and ZOO49NC (see above), the murM chimera was cloned into
the HindIII/NcoI-digested pLS578 plasmid,
yielding the plasmid pM12.
MurM deletion Mutants--
Several simple variants of plasmid
pM3, each carrying incomplete murM genes from strain KY17,
were also constructed.
In plasmid pM13, 50 residues of the C terminus of MurM were deleted by
cloning into the pLS578 plasmid a PCR fragment amplified by the
following pair of primers: ZOO48HI (see above) and MDC355N (5'-AATGCCATGGTTA
In plasmid pM14, 50 residues of the N-terminal of MurM were deleted by
cloning into the pLS578 plasmid a PCR fragment amplified by the
following pair of primers, ZOO49NC (see above) and MDNM68 (5'-ATCAAGCTTAAGGAGGCTATAAA
In plasmid pM15, 10 residues were deleted from the C terminus by
cloning into the pLS578 plasmid the PCR product from the KY17
chromosomal DNA using primers ZOO48HI AND MDC396F
(5'-CATGCCATGGTTAGAAATCAAGAGCAAGTCTTAACAG-3'), which
includes an NcoI restriction site (underlined) and a
premature stop codon (double-underlined).
In plasmid pM16, the segment between residues 240 and 275 was deleted.
To construct this murM deletion mutant we cloned into the
E. coli HindIII/XhoI-digested plasmid pSF30 (that
carries a DNA fragment encoding the last 131 residues of the C-terminal from KY17 MurM) the PCR product obtained with primers ZOO48HI and MMUT3
from the KY17 chromosomal DNA. This PCR product encodes the first 240 amino acid residues from the N terminus. The resulting plasmid, pSF32,
carried a murM gene that coded for a protein equal to KY17
except for the deletion between residues 240 and 275. The
murM with the deletion was then amplified with primers
ZOO48HI and ZOO49NC (see above) and cloned into the pneumococcal
plasmid pLS578, yielding the plasmid pM16.
Single Residue MurM Mutants--
The murM allele from
KY17 was also mutated to test the possible importance of some amino
acid residues for the specificity of the MurM-catalyzed reaction. The
particular residues tested were threonine in position 260 and glutamine
in position 27 of the MurM protein. In plasmid pM17 the threonine
residue at position 260 of the KY17 murM was mutated to
lysine, whereas in plasmids pM18 and pM19 the glutamine residues at
position 27 were mutated to either glutamate (pM18) or to threonine (pM19).
The following procedures were used. First, the murM gene was
amplified from chromosomal DNA of strain KY17 using primers ZOO48HI and
ZOO49NC (see above) and cloned into the
HindIII/NcoI site of pSF22, yielding the plasmid
pSF23. Then the threonine in the position 260 of the cloned
murM was mutated to a lysine using the QuikChange
site-directed mutagenesis kit (Stratagene) and the primer PDT260K
(5'-GAGCCTTGGAAGAGAAGTTTACTGAGTCGACTCGC-3') and its reverse
PRT260K, yielding the plasmid pSF33 (the mutated codon is in
boldface). The glutamine residue in position 27 was also mutated by the
same procedure to a glutamate with the primer PDQ27E
(5'-GAATTAGCCAATGTATTAGAAAGTAGTGCTTGGGAAG-3') and its
reverse PRQ27E, and to a threonine with the primer PDQ27T (5'-GAATTAGCCAATGTATTAACCAGTAGTGCTTGGGAAG-3') and its
reverse, yielding the plasmids pSF34 and pSF35, respectively (the
mutated codons are in boldface). Both mutations were confirmed by
sequencing. Eventually the mutant murM genes were then
transferred to the pneumococcal plasmid pLS578.
Cell Wall Preparation and Enzymatic Digestion--
Pneumococcal
cell walls were prepared by a previously published method (2, 15)
except for the process of breaking the cells that was done by shaking
with acid-washed glass beads with the help of FastPrep FP120 (BIO 101 Inc.). Cell wall material (2 mg) was suspended in 25 mM
sodium phosphate buffer, pH 7.4, and treated with affinity-purified
pneumococcal amidase (5-10 µg) at 37 °C for 12-18 h with
constant stirring. The products were dried, the precipitate was washed
with acetone, and the peptides were extracted with
acetonitrile-isopropanol-water (25:25:50, v/v) containing 0.1%
trifluoroacetic acid as already described (2, 15, 16). After removal of
the solvents by evaporation in a SpeedVac, the peptides were dissolved
in 0.1% trifluoroacetic acid.
Separation and Analysis of the Cell Wall Stem
Peptides--
Peptides were separated with a Shimadzu LC-10AVP HPLC
system, as described previously (2). The column used was a Vydac model
218TP54 (The Separations Group). Peptides were eluted with an 80-min
linear gradient from 0 to 15% acetonitrile (Fisher) in 0.1%
trifluoroacetic acid (Pierce) pumped at a flow rate of 0.5 ml/min. The
eluted fractions were detected and quantified by determination of their
UV absorption at 210 nm (A210).
Isolation and Analysis of S. pneumoniae Peptidoglycan
Precursors--
For analysis of cytoplasmic (UDP-linked) peptidoglycan
precursors of S. pneumoniae cultures were grown in C+Y
medium to an A590 nm of 0.3 at which time
vancomycin was added at a final concentration of 5 µg/ml (10× MIC).
The cultures were incubated for 60 min, harvested by centrifugation,
and washed with 50 mM Tris-HCl, pH 8.0. The UDP-linked cell
wall precursors were extracted by cold 5% trichloroacetic acid for 30 min. The extract containing the pool of precursors was separated by gel
filtration on a Sephadex G-25 column (Amersham Pharmacia Biotech) and
eluted with water. The precursor compounds were then applied to a 3.9- × 30-mm reversed-phase column (µBondapack C18, Waters) as previously
described (17) except that the UDP-linked precursors were eluted with
an 80-min linear gradient from 0 to 15% of acetonitrile (Fisher) in
0.1% trifluoroacetic acid (Pierce) pumped at a flow rate of 0.5 ml/min. The eluted fractions were detected and quantified by
determination of their UV absorption at 254 nm.
Lipid-linked cell wall precursors were prepared essentially as
described by Kohlrausch and Holtje (18). Cultures were grown in C+Y
medium to an A590 nm of 0.3 at which time
vancomycin at a final concentration of 5 µg/ml (10× MIC) was added.
The cultures were incubated for one additional generation period,
harvested by centrifugation, and washed with 50 mM Tris-HCl
buffer, pH 8.0. The lipid-linked precursors were extracted with
ice-cold n-butanol/6 M pyridinium acetate (pH 4)
(4:1) by shaking with glass beads with the help of FastPrep FP120 (BIO
101 Inc.). The organic phase was collected, washed twice with 1 volume
of water, and dried in a SpeedVac. The lipid precursors in the organic
extraction phase were hydrolyzed with 0.1 M HCl for 15 min
in a boiling water bath to yield GlcNAc The Addition of Peptide Branches to the S. pneumoniae Muropeptides
Occurs in the Plasma Membrane Fraction--
To identify the step of
the cell wall biosynthetic pathway in which serine or alanine are added
to the
The lipid extract of strain Pen6 showed accumulation of 2 major peaks
(Fig. 1A). Several additional minor peaks were also present. The nature of these is not known at the present time. Amino
acid analysis of peak a showed the presence of glutamic acid, lysine, alanine, and serine in the molar ratios of 1.0, 0.8, 3.8, and 1.1, which is consistent with the structure of a disaccharide
pentapeptide carrying a seryl-alanine branch (Glu 1.0, Lys 1.0, Ala
4.0, Ser 1.0). Amino acid analysis of the second peak b
showed the presence of glutamic acid (1.0), lysine (0.8), and alanine
(4.4) with small amounts of contaminating serine consistent with the
structure of peak b as the disaccharide pentapeptide containing an alanyl-alanine branch. The small deficit in alanine content (4.4 mol instead of the expected 5.0) together with the presence of small amounts of serine indicate peak b also
contains small amounts of seryl-alanine-containing muropeptide. The
relative amounts of peak a to peak b was 59 and
41%, respectively, similar to the ratio of seryl-alanine (55%)- and
alanyl-alanine (45%)-containing muropeptides in the peptidoglycan of
strain Pen6 (Table II) (4).
To rule out that the reaction catalyzed by MurM (addition of serine or
alanine to the Alterations in the Cell Wall Composition of S. pneumoniae Strain
R36A Carrying Different murM Alleles on Plasmids--
Three
murM alleles described previously (5) were cloned in the
pLS578 plasmid and transformed into strain R36A (a
penicillin-susceptible laboratory strain with a relatively low
percentage of branched stem peptides). Two of the murM
alleles cloned into pLS758 had mosaic structure and came from the
penicillin-resistant clinical isolates DE1 and KY17 (5). The third
murM came from strain R36A. The peptidoglycan of the two
penicillin-resistant strains had a high proportion of branched
muropeptides: 77% in strain DE1 and 84% in KY17, as compared with
strain R36A in which only 41% of muropeptides had branched structure.
The two penicillin-resistant strains also had distinct cell wall stem
peptide composition that differed from the composition of strain R36A
(see the HPLC chromatograms of Figs. 2
and 3; see also Table
III). Strain DE1 had a high percentage of
branched peptides with alanine as the first residue of the cross-bridge
(monomeric peptide I, 23.9%; dimeric peptide VI, 28.8%). The
peptidoglycan of strain KY17 had an increased percentage of branched
peptides with serine as the first residue of the cross-bridge (monomeric peptide 3, 29.5%; dimeric peptide 7, 21%). Introduction of
the cloned murM alleles in plasmid pLS578 into strain R36A caused a significant increase in the proportion of branched peptides in
the peptidoglycan of the transformants, from 41% in the recipient strain to 93 and 90% in transformants R36ApM1 and R36ApM2,
respectively. Furthermore, the shifts in peptidoglycan composition
observed in the transformants closely paralleled the composition of
peptidoglycan in strains DE1 and KY17. In R36ApM2 carrying the
murM allele from DE1, the amount of peptides with
alanyl-alanine branches increased from 1.7 to 24.7% (peptide I) and
from 4.0 to 40.8% (peptide VI). In the peptidoglycan of R36ApM3
carrying the murM allele from strain KY17, the amount of
peptides with seryl-alanine branches increased from 2.7 to 19.9%
(peptide III) and from 6.5 to 23.3% (peptide 7).
Although the peptidoglycan composition of the R36A transformants and
the respective clinical isolates from which the two murM alleles were amplified was very similar, there were also several differences. For instance, strain DE1 had a higher percentage of linear
monomeric peptide 1 and 6 than the R36ApM2 (Table III). Such variation
may be the result of a higher expression of the cloned murM
alleles, which are under the control of the strong and conserved
promoter of pLS578 in the transformant (10). This is also suggested by
the fact that, when the murM allele from R36A was introduced
through R36ApM1, the peptidoglycan of the transformant showed a major
increase in the percentage of branched peptides from 41 to 93% whereas
the proportion of the branched peptide, containing serine and alanine
or only alanine in the cross-bridge composition, remained unaltered
(Table III and Fig. 4). In the
peptidoglycan of R36ApM1 carrying the murM allele from strain R36A in the plasmid (in addition to the chromosomal encoded), the amount of peptides with seryl-alanine branches increased from 2.7 to 20.2% (peptide III) and from 6.5 to 24.5% (peptide 7).
These results show that, although there are two copies of
murM (one in the chromosome and one in the pLS578 plasmid)
in the R36A transformants, the composition of the peptidoglycan of
these strains is determined by the plasmid-encoded murM,
present in a much higher copy number or under the control of a stronger
promoter. Additionally, the overexpression of the murM
protein did not alter the specificity of the reaction. The strain R36A,
with only a copy of the murM in the chromosome, had a small
percentage of branched peptides that were identical to the transformant
overexpressing the same protein in the pLS578 plasmid.
Besides the changed peptidoglycan composition no major changes were
apparent in other properties of strain R36A transformed with the
various murM alleles: The growth rate (mass doubling time)
of strain R36A carrying pLS578 without insert was 28 min and with
insert (e.g. R36ApM2) was 31 min. In none of the
transformants carrying murM alleles from resistant strains
was there any observable increase in the penicillin MIC value of strain
R36A (MIC = 0.032 µg/ml as determined by E test).
Determination of the Amino Acid Sequence That Controls the
Specificity of the MurM-catalyzed Branching Reaction--
Strain DE1
and the plasmid transformant R36ApM2 carrying the murM
allele of DE1 produced peptidoglycan that was enriched for alanyl-alanine-containing branched peptides. In strain KY17 and its
corresponding plasmid transformant R36ApM3, the peptidoglycan was
enriched for seryl-alanine-containing branches. Comparison of the
different mosaic murM sequences of these strains and the peptidoglycan composition suggested that the sequence that defines specificity of the branching reaction resides in the polymorphic regions of murM, specifically within the amino acid residues
229-300 (see Fig. 4C). To more precisely locate this
region, chimeric mutants of murM were constructed from
segments of the murM gene from strains DE1, KY17, and R36A
(Fig. 3).
The mutant alleles that resulted from permuting different regions of
the MurM protein from strains R36A, KY17, and DE1 were cloned into
plasmid pLS578, which was then introduced into strain R36A by genetic
transformation, and the peptidoglycan composition of the transformants
was analyzed.
Plasmid pM9 was constructed to carry a murM allele that
encoded a protein with residues 1 through 240 from the R36A MurM, and
residues 241 through 406 were from strain DE1. The peptidoglycan of
transformant R36ApM9 was enriched for branched peptides with alanine as
the first residue of the cross-bridge (81% of all branched peptides),
and this was similar to the composition of peptidoglycan in strain DE1
and in R36ApM2. Virtually identical results were obtained with
construct pM10 in which the cloned MurM had residues 1 through 240 that
were derived from strain KY17 and residues 241 through 406 came from
DE1. In transformant R36ApM10, the percentage of branched peptides with
alanine as the first residue of the cross-bridge was 80%. These
results suggested that the control of specificity of the MurM-catalyzed
reaction was within the 241-406 sequence of the protein.
To further define this region two additional fusion mutants were
constructed. Plasmid pM11 had a cloned MurM with the entire amino acid
sequence derived from the MurM of strain KY17 except for the sequence
between residues 244 and 298, which was identical to that of the MurM
from strain DE1. The peptidoglycan of transformant R36ApM11 was
enriched for branched peptides with only alanine residues in the
cross-bridge (82%). These results narrowed down the region responsible
for the reaction specificity to the sequence between residues 244 and
298. In the second fusion mutant pM12, the entire cloned MurM was from
strain KY17 except for the sequence between residues 244 and 274, which
came from strain DE1. The peptidoglycan composition of transformant
R36ApM12 was again very similar to that of strain DE1 or transformants
R36ApM11 and R36ApM2: 81% of the branched peptides of this
transformant were composed of alanyl-alanine.
Attempts to pinpoint individual amino acid residues within the 30-amino
acid sequence between residues 244 and 274 were only partially
successful. In the MurM from strain KY17 (which incorporates mainly
serine) the amino acid residue at position 260 is threonine, whereas in
the MurM from strain DE1 (which incorporates mainly alanine) position
260 is a lysine. In plasmid pM17, carrying an intact murM
allele from strain KY17, the codon encoding the threonine at position
260 was mutated by site-directed mutagenesis to one that encoded
lysine. In the corresponding transformant R36ApM17, the proportion of
branched peptides increased from 41 to 92% indicating that the mutant
protein was highly active. The increased amount of branched peptides is
very similar to the value of 93% in the R36ApM1 transformant. However,
the percentage of the branched peptides that had alanine as the first
residue of the cross-bridge was only increased from 27% (in strain
R36ApM3) to 46% in R36ApM17. In transformants carrying the entire
30-amino acid sequence between residues 244 and 274 from strain DE1,
the corresponding increase in alanine containing cross-bridges was much
larger: from 27 to 81% (see Fig. 5).
These results indicate that residues other than lysine in position 260 are also involved with defining the specificity of MurM.
In two other MurM mutants cloned into pLS578, the glutamine residue in
position 27 of the MurM of strain KY17 was mutated to glutamate (in
pM18) or to threonine (in pM19). This amino acid has been suggested as
being involved in the catalytic site of a homologous protein in
Lactobacillus viridescens (21). The proportion of
branched peptides was found to be normally increased in transformants
carrying these mutant forms of the KY17 murM allele, but
there was no change in the chemical composition of the branches.
Analysis of MurM Deletion Mutants--
Several deletion mutants
were constructed from the murM allele of strain KY17, and
the deleted murMs cloned into pLS578 were introduced into
strain R36A by genetic transformation. No activity could be detected by
plasmids carrying murM genes from which 50 amino acid
residues were removed at the C terminus (pM13), the N terminus (pM14),
or 10 amino acids removed at the C terminus (pM15) or in plasmids in
which the sequence of MurM between residues 240 and 274 were deleted.
The peptidoglycan of such transformants showed no increase in the
percentage of branched structured stem peptides (see Fig. 5).
Construction of a Pen6 murM Null Mutant and Complementation with
murM Encoded in a Plasmid--
To rule out the possibility that the
R36A chromosome encoded MurM may have a significant contribution in the
alteration in the cell wall composition, we constructed a mutant in
which the murM gene was replaced by the erm
marker from the pJDC9 plasmid (22). Confirmation of the
erythromycin-resistant Pen6 murM null mutant was obtained by
sequencing the PCR fragment amplified with primers ZOO30 and ZOO45EC
(including the murMN region). Cell wall analysis showed no
branched structured stem peptides in the Pen6
Additionally, we cloned a derivative from the DE1 murM
allele, a chimeric murM mutant in which residues 1-240 came from the MurM of R36A, and residues 241-406 from the MurM of strain DE1. This
construct specifically incorporated alanine when cloned into strain
R36A (R36ApM9) (Fig. 5). This murM allele was cloned
together with the murN gene in pLS578 (pM9N) and transformed
into the Pen6 murM null mutant. The peptidoglycan of this
construct was enriched in branched peptides with alanine as the first
residue of the cross-bridge, as expected from the cell wall composition
of DE1 strain. The percentage of linear peptides 1 and 4 was reduced to
1.0 and 0.8%, respectively. Similar values, 0.9 and 0.8, were found in
R36ApM9. Concomitantly, there was accumulation of branched stem
peptides with only alanine in the cross-bridge. The proportion of
peptide I increased from 0.1 to 24.3% and peptide VI from 0.6 to
33.2%. The corresponding values in R36ApM9 were 26 and 45.8%, respectively. The total amount of branched peptides increased from 6%
in the Pen6
These results make it unlikely that the chromosomally encoded MurM from
R36A has made a significant contribution to the cell wall structure in
R36A transformants carrying the plasmid encoded MurM.
A unique feature of the peptidoglycan of S. pneumoniae
is that it contains both linear as well as branched stem peptide
residues, and dimeric and higher oligomeric components are cross-linked both directly as well as indirectly through short cross-bridges composed of dipeptides of either alanyl-alanine or seryl-alanine residues. This feature of the pneumococcal cell wall positions it as a
mixed A3 alpha and A1 alpha type in the taxonomic scheme proposed by
Schleifer and Kandler (23). The introduction of the RP-HPLC
method for the analysis of pneumococcal cell walls (2, 24, 25) has
resolved the pneumococcal peptidoglycan to a large number (over 25) of
muropeptide components allowing the identification of the chemical
structures of these linear and branched cell wall components.
Examination of a large number of S. pneumoniae clinical
isolates recovered from different isolation and geographic sites, at
different time periods and expressing a variety of different capsular
serotypes, showed that the muropeptide composition of the cell walls
was preserved with remarkable accuracy from strain to strain,
suggesting the existence of a cell wall composition that is specific
for the species of S. pneumoniae (1-3). The notion of
precise genetic control over cell wall composition has received new
support through the examination of cell wall composition in
penicillin-resistant S. pneumoniae clinical isolates. Several genetic lineages of these resistant bacteria showed an unusually large proportion of branched structured muropeptides in their
cell walls, and the cell wall composition also appeared to be specific
for the particular clone in terms of the chemical nature of the
branched peptides: In some of the clones the amino acid serine
predominated as the first amino acid of the dipeptide branch, whereas
in other clones the first amino acid was alanine.
What made this structure variation particularly interesting was the
observation made in 1990 that the abnormal, highly branched, cell wall
composition of a penicillin-resistant South African isolate of S. pneumoniae was co-transferred along with the penicillin resistance
trait during genetic transformation in which resistance to penicillin
was selected for (8, 15). This finding suggested some functional
connection between the abundance of branched stem peptides in the cell
wall and resistance to penicillin.
The recent identification of the murMN operon in S. pneumoniae has opened up this area for new exploration.
Inactivation of the murMN operon was reported to cause a
disappearance of branched stem peptides from the cell wall and also a
complete suppression of the penicillin-resistant phenotype. This
indicated to us that further exploration of the mode of action and
regulation of this operon would yield valuable new insights both into
the mechanism of control of cell wall structure and also into the
mechanism of expression of penicillin resistance (4).
Comparison of the DNA sequences of murM and murN
genes was determined in a large number of penicillin-susceptible and
penicillin-resistant clinical isolates of S. pneumoniae.
Although the structure of murN genes appeared to be highly
conserved showing little sequence variation, a considerable amount of
polymorphism was noted in murM genes identified in several
penicillin-resistant S. pneumoniae isolates (5). The site of
involvement of these two genes in the production of the dipeptide
branches was clarified (6). Selective inactivation of murN
produced a unique type of peptidoglycan not seen among clinical
isolates: Such bacteria contained branched stem peptides made up of
only a single amino acid residue, the chemical nature of which remained
the same as in the parental strain. Besides reduction of the dipeptide
branches to a single amino acid, there was no other change in the
nature and/or proportion of various structurally distinct muropeptides
or in the degree of peptidoglycan cross-linking in these
murN mutants. These observations identified the role of
murN as the determinant involved with the addition of the
second amino acid residue to the dipeptide branches. In concordance
with the highly conserved sequence of murN, the nature of
the second amino acid residue in the branched peptides was invariably
alanine in all the large number of S. pneumoniae isolates examined.
The results of these studies suggested that the primary determinant
responsible for the clone-specific variation in the structure of the
pneumococcal cell walls was the murM gene, and the results of experiments described in this communication provide unequivocal evidence for this proposition.
The evidence identifying murM as the gene primarily
responsible for the clone-specific variation in the pneumococcal cell wall was based on an experimental system in which the various murM alleles identified in S. pneumoniae isolates
were cloned in the pneumococcal plasmid pLS578, which is capable of
independent replication in pneumococci (10). These recombinant plasmids were then introduced into the isogenic background of the
penicillin-susceptible S. pneumoniae strain R36A, and the
activity and specificity of the particular murM allele were
assessed by determining the impact of the plasmid-borne murM
genes on the composition of the peptidoglycan of such transformants.
The particular murM alleles used in most of these genetic
crosses were murMA, carried by penicillin-susceptible strains of S. pneumoniae, murMB3 carried by the
penicillin-resistant strain DE1, and murMB5 carried by the
penicillin-resistant strain KY17 (5). Strains carrying murMA
produce branched peptides the majority of which (71%) have serine as
the first amino acid residue. Strains carrying the murMB3
allele have branched peptides in which most of the amino acid residues
(82%) in the first position of the branches is alanine. In strains
that carry the murMB5 allele, the first amino acid residue
in the branches (78%) is serine. Analysis of these genetic crosses
demonstrated the importance of the particular murM allele
both for the percentage representation of branched peptides in the cell
wall and also for their chemical nature. The experiments documented in
Fig. 5 indicate that the abundance of branched muropeptides in the cell
wall depends on the rate of transcription and/or copy number of
murM. Introduction of each one of the murM
alleles on plasmid pLS578, even the allele murMA identical
to the one resident on the chromosome of the recipient cell R36A,
caused a massive increase in the percentage of branched peptides in the
cell wall. The most likely interpretation of this finding is that the
well documented activity of the powerful promoter present on plasmid
pLS578 (10) causes extensive transcription of murM in the transformants.
The experiments with the genetic crosses also provide clear
documentation that the chemical nature of the branched peptides, i.e. whether the first amino acid residue is serine or
alanine, is primarily determined by the structure of the MurM protein. The composition of the peptidoglycan of strain R36A that was the common
recipient in all the genetic crosses has undergone extensive changes
from serine-rich to alanine-rich branched peptides and also in the
percentage of total branched peptides by the introduction of the
appropriate murM alleles.
Experiments with the murM deletion mutants showed that these
activities of the MurM protein depended on intact C and N termini of
the protein. Deletion of 10 or 50 amino acid residues from the C
terminus or removal of 50 amino acids from the N terminus caused
inactivation of the MurM protein.
The chemical specificity of murM, i.e. whether
the protein catalyzed the introduction of serine or alanine as the
first residue of the branched peptides, was localized to a 30-amino
acid sequence between residues 244 and 274 of the protein.
Biochemical analysis of the cell wall precursor pools has identified
the lipid II as the substrate of the MurM protein. This is in contrast
to the recently described case for Lactobacillus viridescens in which cell wall branched peptides were shown
to be attached to the disaccharide pentapeptide precursor in the cytoplasmic stage of cell wall biosynthesis (21, 26). Our data show
that in S. pneumoniae this reaction takes place in the plasma membrane.
The large variation in peptidoglycan composition identified in the
plasmid transformants did not seem to cause any perceptible growth
defect in the transformants nor in the morphology of the bacteria.
Despite the radical changes in the proportion of branched peptides and
also in the chemical nature of the branches, other aspects of the
structure of peptidoglycan such as the proportion of monomeric and
oligomeric muropeptides or the degree of cross-linking remained
unchanged in the genetic transformants. In the plasmid transformants
R36ApM2 and R36ApM3, the total number of branched muropeptides
increased from 41% in strain R36A to 90 and 89%, respectively, in the
transformants. Despite this radical change in wall composition,
bacterial growth was not perceptively affected indicating that the
penicillin binding proteins of the penicillin-susceptible strain R36A
were able to utilize either linear or branched peptides with equal
facility for cell wall biosynthesis.
It is also clear from the results that the introduction of
murM alleles from penicillin-resistant bacteria to the
penicillin-susceptible recipient R36A did not cause any increase in
penicillin resistance. It seems that the presence of low affinity
penicillin binding proteins remains an indispensable prerequisite for
the resistant phenotype. The mechanism responsible for the dramatic
loss of penicillin resistance in S. pneumoniae with
inactivated murMN is the subject of a forthcoming
communication.2
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
murM mutant was confirmed by PCR amplification and
subsequent sequencing.



-1,4-MurNAc peptide
derivatives. Before HPLC separation, one volume of 0.5 M
borate buffer, pH 9.0, was added to this muramyl residue-containing
fraction. The muramyl residues were then reduced to muramitol
derivatives with sodium borohydride and analyzed by reverse-phased
HPLC, as previously described (19). The amino acid composition (20) of
the eluted peaks was determined at the Rockefeller University
Protein/DNA Technology Center.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-amino group of the muropeptide lysine residues, we
determined the composition of the cytoplasmic and lipid-linked
precursors in the penicillin-resistant S. pneumoniae strain
Pen6 and its murM deletion mutant (Table I). Both cultures were grown to early
exponential phase, at which time vancomycin was added to cause
accumulation of UDP-linked (cytoplasmic) or lipid-linked (plasma
membrane) cell wall precursors. After removal of the lipid carrier by
mild acid hydrolysis, followed by sodium borohydride reduction of the
released muropeptide component(s), these were analyzed by RP-HPLC and
their amino acid compositions were determined. In the lipid extract of
the Pen6 murM null mutant, one major peak c was
identified (Fig. 1A). Two
small additional peaks were also consistently detected. The chemical
nature of these is unknown. Amino acid analysis showed the presence of
glutamic acid, lysine, and alanine in the molar ratio of 1.0, 0.8, and 2.75 suggesting an unsubstituted disaccharide pentapeptide (Glu 1.0, Lys 1.0, Ala 3.0). Peak c had a retention time on the
RP-HPLC column identical to that of the unsubstituted disaccharide
pentapeptide component of Staphylococcus aureus
peptidoglycan (19).
Relevant properties of the strains and plasmids used in this study

View larger version (13K):
[in a new window]
Fig. 1.
Analysis of the cell wall precursors by
RP-HPLC of Pen6 and its murM deletion mutant.
Lipid-linked precursors (A) and UDP-linked precursors
(B) from Pen6 and its murM deletion mutant were
prepared, and its composition was determined by HPLC as described under
"Experimental Procedures."
Cell wall peptide composition of several strains of S. pneumoniae
-amino group of the lysine residue) may also occur in
the cytoplasmic fraction, we analyzed the composition of the UDP-linked
precursors in the Pen6 and its murM null mutant. Extracts
from both strains showed accumulation of a single major peak
a and two smaller peaks (Fig. 1B). Peak
a had the same retention time on the RP-HPLC column as the
UDP-linked disaccharide pentapeptide identified in the cytoplasmic cell
wall precursor fraction of several bacteria (17). The nature of the
smaller peaks is not known.

View larger version (14K):
[in a new window]
Fig. 2.
Analysis of cell wall stem peptides by
RP-HPLC of several strains. Cell walls were prepared from strains
R36A and DE1 and R36A transformant with the murM from DE1
(R36ApM2); strain KY17 and the R36A transformant with the KY17
murM allele (R36ApM3). Peptidoglycan compositions were
analyzed by RP-HPLC.

View larger version (24K):
[in a new window]
Fig. 3.
Structural assignments for the pneumococcal
stem peptides. The structures of the stem peptides found in the
peptidoglycan of S. pneumoniae have been described
previously (2, 24).
Cell wall stem peptide composition of various strains of S. pneumoniae

View larger version (31K):
[in a new window]
Fig. 4.
Role of MurM alleles in defining the chemical
composition of branched cell wall stem peptides. A,
peptidoglycan composition of strains carrying different murM
alleles. B, schematic representation of the mosaic regions
in the murM alleles. The black region indicates
more than 10% divergence relatively to the MurM from the
penicillin-susceptible reference strain R36A. C,
distribution of polymorphic sites among the different MurM proteins.
The murM alleles were sequenced from the
penicillin-susceptible laboratory strain R36A and from the
penicillin-resistant strains listed (5). Numbers above the
sequences (beginning at the first residue of MurM: residue 10)
identify positions at which an amino acid alteration was detected in
one of the MurM proteins. Only positions with altered residues are
shown; residues identical to those in strain R36A are indicated by
dots.

View larger version (37K):
[in a new window]
Fig. 5.
Regions in the MurM proteins that define the
chemical composition of branched stem peptides. The sequence of
murM alleles characteristic of strains R36A
(cross-hatched), DE1 (black), and KY17
(white), and the murM chimera mutants and
murM deletions, are indicated by the drawings.
The percentages of branched peptides that have serine or alanine in the
first position of the cross-bridge are also tabulated for the various
strains and murM constructs.
murM mutant.
The composition of the peptidoglycan was identical to that of
Pen6murMN, a mutant obtained by insertion of a suicide plasmid in the murM gene (4). We cloned two different MurM constructs with different specificities for alanine and serine in the
murM null mutant. One of these constructs was the MurM from
the penicillin-resistant strain KY17, which has serine-rich branched
peptides. Analysis of the cell wall composition showed an accumulation
of a peptide with retention time similar to that of the semi-branched
peptide 3a (data not shown), carrying only a single serine residue in
the cross-bridge (6). This result suggests that the expression of
murN gene in the chromosome with the erm promoter
was not sufficient to fully recover the cell wall composition. To
compensate for this, both genes (the murM allele from KY17
and the murN gene from R36A strain) were cloned in pLS578
under the control of the conserved plasmid promoter and were
transformed into Pen6
murM. The composition of the
peptidoglycan of this transformant (Pen6
murMpM3N) was
rich in serine-containing branched peptides, similar to the composition
found in the KY17 strain (Table II). There was a decrease in the
percentage of linear stem peptide 1 from 41.4% in
Pen6
murM to 1% in the transformant. This value was
similar to the 3.2% found in R36ApM3. There was also a decrease in the
linear dimeric peptide 4 from 45.4% in Pen6
murM to 3.5%
in the transformant. This value was similar to the 0.6% found in
R36ApM3. The proportion of branched peptide 3 increased from 0.1 to
19.3% and so did the corresponding dimeric peptide 7, from 0.4 to 25%
(Table III). The corresponding values for peptides 3 and 7 in the
R36ApM3 transformants were 19.9 and 23.3%, respectively. The
percentage of all branched peptides changed from 6% in the
Pen6
murM mutant to 86% in the transformant carrying the
pM3N plasmid. Of these branched peptides, 75% had serine as the first
residue of the cross-bridge whereas in the remaining 25% the first
residue was alanine. This proportion is very similar to that found in
R36ApM3 (73 and 27%, respectively).
murM mutant to 96% in the transformant with plasmid pM9N.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
| |
ACKNOWLEDGEMENT |
|---|
We are grateful to Dr. Sandford Lacks for plasmid pLS578.
| |
FOOTNOTES |
|---|
* This work was supported in part by a grant from the National Institutes of Health RO1-AI37275 and by the Irene Diamond Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ Supported by grant BD/9071/96 from PRAXIS XXI from Fundação para a Ciência e Tecnologia.
Permanent address: Institute of Theoretical and Experimental
Biophysics, Russian Academy of Sciences, Pushchino, Moscow Region 142292, Russia.
** To whom correspondence should be addressed: Laboratory of Microbiology, The Rockefeller University, 1230 York Ave., New York, NY 10021. Tel.: 212-327-8278; Fax: 212-327-8688; E-mail: tomasz@mail.rockefeller.edu.
Published, JBC Papers in Press, August 24, 2001, DOI 10.1074/jbc.M106425200
2 S. R. Filipe, E. Severina, and A. Tomasz, manuscript in preparation.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: MIC, minimal inhibitory concentration; PCR, polymerase chain reaction; kb, kilobase(s); RP-HPLC, reversed-phase high pressure liquid chromatography; aa, amino acid(s).
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Garcia-Bustos, J.,
and Tomasz, A.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
5415-5419 |
| 2. |
Severin, A.,
and Tomasz, A.
(1996)
J. Bacteriol.
178,
168-174 |
| 3. |
Severin, A.,
Figueiredo, A. M.,
and Tomasz, A.
(1996)
J. Bacteriol.
178,
1788-1792 |
| 4. |
Filipe, S. R.,
and Tomasz, A.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
4891-4896 |
| 5. |
Filipe, S. R.,
Severina, E.,
and Tomasz, A.
(2000)
J. Bacteriol.
182,
6798-6805 |
| 6. |
Filipe, S. R.,
Pinho, M. G.,
and Tomasz, A.
(2000)
J. Biol. Chem.
275,
27768-27774 |
| 7. | Avery, O. T., Macleod, C. M., and McCarty, M. (1944) J. Exp. Med. 79, 137-157[Abstract] |
| 8. |
Zighelboim, S.,
and Tomasz, A.
(1980)
Antimicrob. Agents Chemother.
17,
434-442 |
| 9. | Corso, A., Severina, E. P., Petruk, V. F., Mauriz, Y. R., and Tomasz, A. (1998) Microb. Drug Resist. 4, 325-337[Medline] [Order article via Infotrieve] |
| 10. | Lacks, S. A., Ayalew, S., de la Campa, A. G., and Greenberg, B. (2000) Mol. Microbiol. 35, 1089-1098[CrossRef][Medline] [Order article via Infotrieve] |
| 11. | Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. (1996) Current Protocols in Molecular Biology , John Wiley & Sons, New York |
| 12. | Sambrook, J., Fritsch, I., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual , 2nd Ed. , Cold Spring Harbor Laboratory, Cold Spring Harbor, NY |
| 13. | Marmur, J. (1961) J. Mol. Biol. 3, 208-218 |
| 14. |
Pozzi, G.,
Masala, L.,
Iannelli, F.,
Manganelli, R.,
Havarstein, L. S.,
Piccoli, L.,
Simon, D.,
and Morrison, D. A.
(1996)
J. Bacteriol.
178,
6087-6090 |
| 15. |
Garcia-Bustos, J. F.,
Chait, B. T.,
and Tomasz, A.
(1988)
J. Bacteriol.
170,
2143-2147 |
| 16. |
Garcia-Bustos, J. F.,
and Tomasz, A.
(1987)
J. Bacteriol.
169,
447-453 |
| 17. |
Ornelas-Soares, A.,
de Lencastre, H.,
de Jonge, B. L.,
and Tomasz, A.
(1994)
J. Biol. Chem.
269,
27246-27250 |
| 18. |
Kohlrausch, U.,
and Holtje, J. V.
(1991)
J. Bacteriol.
173,
3425-3431 |
| 19. |
de Jonge, B. L.,
Chang, Y. S.,
Gage, D.,
and Tomasz, A.
(1992)
J. Biol. Chem.
267,
11248-11254 |
| 20. | Atherton, D. (1989) in Techniques in Protein Chemistry (Hugli, T. E., ed) , pp. 273-283, Academic Press, New York |
| 21. |
Hedge, S. S.,
and Shrader, T. E.
(2001)
J. Biol. Chem.
276,
6998-7003 |
| 22. | Chen, J. D., and Morrison, D. A. (1988) Gene 64, 155-164[CrossRef][Medline] [Order article via Infotrieve] |
| 23. |
Schleifer, K. H.,
and Kandler, O.
(1972)
Bacteriol. Rev.
36,
407-477 |
| 24. |
Garcia-Bustos, J. F.,
Chait, B. T.,
and Tomasz, A.
(1987)
J. Biol. Chem.
262,
15400-15405 |
| 25. |
Severin, A.,
Schuster, C.,
Hakenbeck, R.,
and Tomasz, A.
(1992)
J. Bacteriol.
174,
5152-5155 |
| 26. |
Plapp, R.,
and Strominger, J. L.
(1970)
J. Biol. Chem.
245,
3675-3682 |
This article has been cited by other articles:
![]() |
A. J. Lloyd, A. M. Gilbey, A. M. Blewett, G. De Pascale, A. El Zoeiby, R. C. Levesque, A. C. Catherwood, A. Tomasz, T. D. H. Bugg, D. I. Roper, et al. Characterization of tRNA-dependent Peptide Bond Formation by MurM in the Synthesis of Streptococcus pneumoniae Peptidoglycan J. Biol. Chem., March 7, 2008; 283(10): 6402 - 6417. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. van Heijenoort Lipid Intermediates in the Biosynthesis of Bacterial Peptidoglycan Microbiol. Mol. Biol. Rev., December 1, 2007; 71(4): 620 - 635. [Abstract] [Full Text] [PDF] |
||||
![]() |
|